AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
A Chest study finds that respiratory or red flag symptoms at baseline increase the likelihood of lung cancer diagnosis within one year after screening. A Nature study identifies glucocorticoid-related genes with causal links to non-small cell lung cancer and constructs a multi-omics prognostic model.
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Meta-analysis of 24 trials found chemoimmunotherapy improved survival in PD-L1-high advanced NSCLC. PPIs and antibiotics were linked to worse durvalumab outcomes, and a chronotherapy trial was retracted.
Hengrui Medicine won NMPA clearance for a Phase II NSCLC trial combining SHR-A2009 ADC with adebrelimab or EGFR-TKI, and with partner Kailera reported up to 12.1% weight loss in a Phase II obesity study of oral ribupatide. SHR-A2009 monotherapy NDA is under review for NSCLC, and cumulative R&D on SHR-A2009 has reached RMB 330 million.
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
Eli Lilly's Retevmo met the primary endpoint in a Phase III lung cancer trial, Merck discontinued its TROP2 ADC MK-6837, and a Tango/Revolution combination showed benefit in pancreatic cancer.
A deep learning pathomics platform called Path-IO accurately predicted outcomes and immunotherapy response in NSCLC patients using routine pathology slides, outperforming the PD-L1 biomarker. The model was validated across multiple cohorts and improved further when combined with radiomics and clinical data. If validated, it could be easily integrated into clinical workflows.
Pfizer's ELREXFIO significantly delayed disease progression in a Phase 3 trial for multiple myeloma, outperforming a standard regimen and strengthening the case for earlier use. Separately, Pfizer completed a real-world study of its lung cancer drug lorlatinib in ROS1-positive NSCLC patients.
Daraxonrasib reduced death risk by 60% versus chemo in Phase 3 pancreatic cancer trial (median OS 13.2 vs 6.7 months). EMA began rolling review; zoldonrasib combo data presented at ESMO GI.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07806773 |
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07793500 |
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) |
RECRUITING | EARLY_PHASE1 |
| NCT07784959 |
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer |
RECRUITING | PHASE1 |
| NCT07778745 |
A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07777822 |
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC |
RECRUITING | PHASE3 |
| NCT07746388 |
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07729670 |
Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07697586 |
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer |
RECRUITING | PHASE2 |
| NCT07692048 |
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC |
NOT_YET_RECRUITING | PHASE1 |
| NCT07689812 |
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. |
NOT_YET_RECRUITING | NA |
